Get the Stockscreener App
53.38
2.99%
1.55
After Hours:
53.38
Bridgebio Pharma Inc stock is traded at $53.38, with a volume of 2.87M.
It is up +2.99% in the last 24 hours and up +8.47% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$51.83
Open:
$51.83
24h Volume:
2.87M
Relative Volume:
1.00
Market Cap:
$10.20B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-22.15
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+3.13%
1M Performance:
+8.47%
6M Performance:
+52.65%
1Y Performance:
+70.54%
1-Day Range:
$51.50
$53.97
1-Week Range:
$49.75
$53.97
52-Week Range:
$21.72
$53.97
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
53.38 | 9.91B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment - Investing.com India
BridgeBio Pharma Inc. recovery potential after sell offJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
BridgeBio Pharma Reports Promising Phase 2 Results for Encaleret in Post-Surgical Hypoparathyroidism, Plans Registrational Study for 2026 - Quiver Quantitative
BridgeBio Pharma says intends to initiate registrational clinical study of Encaleret in 2026 - MarketScreener
80% Success Rate: BridgeBio's Encaleret Normalizes Calcium Levels in Breakthrough Hypoparathyroidism Study - Stock Titan
Chart based analysis of BridgeBio Pharma Inc. trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser
Why is BridgeBio Pharma Inc. stock going down2025 Institutional Moves & Technical Pattern Recognition Alerts - خودرو بانک
Is BridgeBio Pharma Inc. stock a top performer YTDAnalyst Downgrade & Real-Time Market Trend Scan - خودرو بانک
BridgeBio Pharma stock hits 52-week high at $52.85 By Investing.com - Investing.com Nigeria
BridgeBio Pharma Inc. stock momentum explainedJuly 2025 Action & Smart Allocation Stock Tips - Newser
News impact scoring models applied to BridgeBio Pharma Inc.Market Growth Summary & Expert Curated Trade Ideas - Newser
Is it time to cut losses on BridgeBio Pharma Inc.Weekly Gains Report & High Accuracy Trade Signal Alerts - Newser
BridgeBio Pharma stock hits 52-week high at $52.85 - Investing.com
What candlestick patterns are forming on BridgeBio Pharma Inc.Inflation Watch & Risk Adjusted Swing Trade Ideas - Newser
When is the best time to exit BridgeBio Pharma Inc.Global Markets & Long-Term Safe Investment Plans - Newser
Published on: 2025-09-05 07:26:11 - خودرو بانک
Using RSI to spot recovery in BridgeBio Pharma Inc.July 2025 Short Interest & AI Enhanced Execution Alerts - Newser
Backtesting results for BridgeBio Pharma Inc. trading strategies2025 Fundamental Recap & Accurate Trade Setup Notifications - Newser
Published on: 2025-09-04 06:09:36 - Newser
Analyzing recovery setups for BridgeBio Pharma Inc. investorsBull Run & Risk Controlled Swing Trade Alerts - Newser
What’s the analyst consensus on BridgeBio Pharma Inc.2025 Growth vs Value & Weekly Market Pulse Alerts - خودرو بانک
Live market analysis of BridgeBio Pharma Inc.2025 Top Gainers & Fast Gaining Stock Reports - Newser
BridgeBio Pharma shares fall 1.95% after-hours following an investor webinar announcement. - AInvest
BridgeBio Pharma (BBIO) Receives a Rating Update from a Top Analyst - The Globe and Mail
Applying Elliott Wave Theory to BridgeBio Pharma Inc.July 2025 Action & Pattern Based Trade Signal System - Newser
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - The Manila Times
BridgeBio Pharma (BBIO) Rating Reiterated as 'Buy' by HC Wainwright & Co. | BBIO Stock News - GuruFocus
Phase 3 Trial Update: BridgeBio's Breakthrough ADH1 Drug Encaleret Featured in NIH Expert Webinar - Stock Titan
Is BridgeBio Pharma Inc. a good ESG investmentProfit Target & Free Weekly Watchlist of Top Performers - خودرو بانک
Market reaction to BridgeBio Pharma Inc.’s recent newsPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Strategies to average down on BridgeBio Pharma Inc.2025 Top Decliners & Proven Capital Preservation Methods - Newser
Can BridgeBio Pharma Inc. withstand a market correctionMarket Sentiment Report & Entry and Exit Point Strategies - خودرو بانک
Short Interest Drops in BridgeBio Pharma Inc. After RallyMarket Performance Report & Weekly High Momentum Picks - beatles.ru
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism - The Manila Times
BridgeBio Pharma Presents Phase 2 Data on Post-Surgical Hypoparathyroidism and Skeletal Dysplasia at ASBMR Annual Meeting 2025 - Quiver Quantitative
New Treatment Hope: BridgeBio's Encaleret Shows Promise in Post-Surgical Hypoparathyroidism Phase 2 Trial - Stock Titan
What’s next for BridgeBio Pharma Inc. stock priceLayoff News & Community Verified Watchlist Alerts - Newser
Published on: 2025-09-02 04:42:43 - Newser
Tick level data insight on BridgeBio Pharma Inc. volatilityEarnings Overview Summary & Weekly High Return Opportunities - Newser
Is BridgeBio Pharma Inc. a defensive stock2025 Breakouts & Breakdowns & Verified Short-Term Plans - خودرو بانک
BridgeBio Pharma: Promising Phase 3 Data and Strong Financial Performance Justify Buy Rating - TipRanks
Tools to monitor BridgeBio Pharma Inc. recovery probabilityPortfolio Risk Report & Daily Chart Pattern Signal Reports - Newser
How does BridgeBio Pharma Inc. score in quality rankingsJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - khodrobank.com
BridgeBio Pharma Inc. stock volume spike explained2025 Pullback Review & Pattern Based Trade Signal System - Newser
Reversal indicators forming on BridgeBio Pharma Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):